After hours: 4:34PM EDT
|Bid||112.76 x 1000|
|Ask||112.75 x 1000|
|Day's Range||110.32 - 113.75|
|52 Week Range||47.78 - 117.98|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||115.90|
MADISON, Wis., June 26, 2019 /PRNewswire/ -- Less than 20 months after breaking ground, Exact Sciences today opened the doors on its new, 169,000 square foot clinical laboratory and warehouse on the City of Madison's near west side. Exact Sciences is a biotechnology company focused on delivering life-changing innovations in earlier cancer detection. The laboratory opened Wednesday will process Cologuard, the company's colorectal cancer screening test.
Every investor in Exact Sciences Corporation (NASDAQ:EXAS) should be aware of the most powerful shareholder groups...
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Wendys Co (NASDAQ: WEN ) is one of his absolute favorites. Cramer is a buyer of Zoetis Inc (NYSE: ZTS ). He added that the stock hit another ...
MADISON, Wis., May 31, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Exact Sciences Corporation's (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on...
Exact Sciences Corp NASDAQ:EXASView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for EXAS with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $1.78 billion over the last one-month into ETFs that hold EXAS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. "These pancreatic cancer data showcase the strength of our marker discovery collaboration with Mayo Clinic, a partnership that is fueling our product pipeline," said Kevin Conroy, chairman and CEO of Exact Sciences.
SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes. Despite recent efforts to positively impact colorectal cancer screening rates in the US, one-in-three Americans ages 50 to 75 are not up to date with recommended screening.i New research suggests the Cologuard test can help screen more people.
Exact Sciences Corp., the Madison-based maker of the Cologuard take-home colon cancer test and one of the largest public companies in Wisconsin, is reportedly returning $61,000 it received from the Wisconsin Economic Development Corp. because a certain number of jobs the money was intended for were created outside of Wisconsin. In 2015, Exact Sciences was approved by the WEDC to receive up to $9 million in tax credits if it added at least 750 jobs and made a capital investment of $26 million by 2020. Under the agreement, Exact Sciences would receive the WEDC tax incentives by investing in capital expenditures in Wisconsin and creating 758 new full-time positions – with an average wage of $24.47 per hour – in the state by Dec. 31, 2020.
Sometimes the U.S. stock market sends a clear, unambiguous message. The message the stock market sent during Federal Reserve Chairman Jerome Powell’s press conference Wednesday says that the market is vulnerable. • The chart shows that the stock market rose immediately after the Fed decision was announced.
MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.
The Madison, Wisconsin-based company said it had a loss of 66 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
The company raised its guidance for its fiscal 2019, anticipating revenues between $725 million and $740 million.
- Estimated Cologuard market share increased to 4.6 percent during the first quarter - Nearly 14,000 health care providers ordered their initial Cologuard test during the first quarter, and more than 160,000 ...
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / EXACT Sciences Corp. (NASDAQ: EXAS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM ...